Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in T-LGL Leukemia
NCT00345345Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Oct 2006
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in T-cell large granular lymphocytic leukemia, sponsored by National Heart, Lung, and Blood Institute. Started Oct 2006; status: completed.
02
Drugs
alemtuzumab
03
Conditions
T-cell large granular lymphocytic leukemia
Beyond the preview
Go deeper on NCT00345345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00345345.